Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Advanced Renal Cell Carcinoma
NCT00053820Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Jul 2002
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of aldesleukin and fluorouracil in renal cell carcinoma (RCC) (2 arms), sponsored by Medical Research Council. Primary endpoints: Overall Survival and Progression-Free Survival. Started Jul 2002; status: completed.
02
Drugs
aldesleukinfluorouracil
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00053820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053820.